Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Zydus will carry out early-stage development. (Image Credits: Pixabay) Zydus Lifesciences Limited on Tuesday announced its focus on the development of a combination vaccine against shigellosis and ...

Zydus Lifesciences Ltd on Wednesday said the Mexican regulatory authority has granted marketing approval for Mamitra, a Trastuzumab biosimilar used to treat various types of cancer. Following the ...

Zydus Lifesciences on Wednesday (February 26, 2025) said it is introducing a vaccine for protection against new strain of influenza virus. “The company is introducing country’s first flu ...

Zydus Lifesciences Limited (Formerly known ... Oxemia. It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla ...

Ahmedabad-based Zydus Lifesciences is set to launch the vaccine VaxiFlu-4 to combat a new strain of the influenza virus, as per the WHO-recommended composition of quadrivalent influenza virus ...

Zydus Lifesciences Limited received final approval from the US Food and Drug Administration (USFDA) to manufacture Ketoconazole Shampoo, 2 per cent, according to the announcement issued by the ...

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...